WorldCare Clinical Introduces New Service for Oncology Imaging Studies Involving Immune-Related Response Criteria (irRC)
New Service Enables Combination Tumor Assessments using both RECIST and irRC
WorldCare Clinical, LLC (WCC), a CRO focused on maximizing the precision and accuracy of independent assessments in clinical trials, today announced a new service that enables efficient capture and analysis of both standard tumor assessment, such as RECIST (Response Evaluation Criteria in Solid Tumors), and the newer immune-related response criteria (irRC) simultaneously. Developed in collaboration with leading academic researchers, WCC’s method has been validated and is being used to evaluate new immune-related treatments.
WCC developed its combination case report form (CRF) to facilitate concurrent tumor assessments using both methods. The new service was designed for sponsors developing immunotherapeutic agents who want to analyze performance using irRC, but also want to capture RECIST responses until the newer irRC becomes more established.
“Employing a combined approach to tumor assessment allows for time savings when performing the imaging interpretation, resulting in a significant cost savings to the sponsor,” said Richard Walovitch, Ph.D., president of WorldCare Clinical. “Using our combination CRF, we’re able to programmatically calculate the response using the criteria of both methods.”
WCC Director of Software Engineering Patrick Chokron will present on the benefits of combining both tumor assessment approaches at the upcoming Immunomodulatory Therapeutic Antibodies for Cancer conference, August 13-15, 2013 in Boston. Chokron’s presentation, “Image Assessment in Immunotherapeutic Trials: Combining irRC and RECIST 1.1,” will take place at the Hilton Boston Back Bay Hotel on Thursday, August 15, 2013 at 12:00 p.m.
For more information on WCC’s services for oncology imaging studies, call (888) 816-4721 or visit www.wcclinical.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
